The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer

By Ligibel Jennifer A.   Winer Eric P.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 2, 2003-04 ,pp. : 215-221

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer

By Montemurro Filippo   Rossi Valentina   Geuna Elena   Valabrega Giorgio   Martinello Rossella   Milani Andrea   Aglietta Massimo  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 15, 2012-10 ,pp. : 2143-2156

Informa Healthcare

Access to resources Recommend Favorite

Physical activity and survival of postmenopausal, hormone receptor–positive breast cancer patients: Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study

By Glas Nienke A.   Fontein Duveken B. Y.   Bastiaannet Esther   Pijpe Anouk   De Craen Anton J. M.   Liefers Gerrit-Jan   Nortier Hans J. W. R.   Haes Hanneke J. C. J. M.   Velde Cornelis J. H.   Leeuwen Flora E.  

Cancer, Vol. 120, Iss. 18, 2014-09 ,pp. : 2847-2854

Blackwell Publishing

Access to resources Recommend Favorite

Switching to adjuvant exemestane after tamoxifen improves disease-free survival in postmenopausal women with hormone receptor-positive early breast cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 23, Iss. 5, 2007-05 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Fulvestrant: A Review of its Use in Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women with Disease Progression following Antiestrogen Therapy

By McKeage K.   Curran M.P.   Plosker G.L.  

Drugs, Vol. 64, Iss. 6, 2004-01 ,pp. : 633-648

Adis International

Access to resources Recommend Favorite